Results 161 to 170 of about 178,297 (335)

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

220. Chemotherapy in Combination with T-Cell Therapy Results in Significant Antitumor Activity and Improved Clinical Outcomes for EBV-Associated Nasopharyngeal Carcinoma [PDF]

, 2011

openalex   +1 more source

Reconstitution of T cell immunity against EBV in the immunocompromised host by adoptive transfer of peptide-stimulated T cells after allogeneic stem cell transplantation [PDF]

, 2021
María Fernanda Lammoglia Cobo, Julia Ritter, Regina Gary, Volkhard Seitz, Josef Mautner, Michael Aigner, Simon Völkl, Stefanie Schaffer, Stephanie Moi, Anke Seegebarth, Heiko Bruns, Wolf Rösler, Kerstin Amann, Maike Büttner‐Herold, Steffen Hennig, Andréas Mackensen, Michael Hummel, Andreas Moosmann, Armin Gerbitz   +18 more
openalex   +1 more source

EBV & lymphoma

HemaSphere, 2019
openaire   +3 more sources

Newly identified properties of known pharmaceuticals and myxobacterial small molecules revealed by screening for autophagy modulators

The FEBS Journal, EarlyView.
Autophagy is a cellular degradation process involved in, for example, immune responses to pathogens and neurodegeneration. To identify modulators of autophagy, we developed a microscopy‐based screening assay and identified previously unknown autophagy‐modulating activities in known drugs and natural products from myxobacteria and fungi.
Janine Fichtner, Yan Yan Beer, H. G. Mauricio Ramm, Sabrina Mühlen, Frank Surup, Jennifer Herrmann, Toni Luise Meister, Stephanie Pfaender, Ursula Bilitewski, Mark Brönstrup, Rolf Müller, Manfred Wirth, Eeva‐Liisa Eskelinen, Ingo Schmitz   +13 more
wiley   +1 more source

Novel mechanisms of EBV-induced oncogenesis

, 2012
Nancy Raab‐Traub
openalex   +1 more source

Differential regulation of translational stress responses by herpesvirus ubiquitin deconjugases

The FEBS Journal, EarlyView.
Translating viral mRNAs is challenging due to structural features that may slow translation or induce ribosome stalling. The viral ubiquitin deconjugases encoded by human pathogenic herpesviruses regulate the cellular response to ribosomal stress by inhibiting various branches of the Ribosomal Quality Control (RQC) and activating Ribosomal Stress ...
Jiangnan Liu, Noemi Nagy, Carlos Mario Ayala‐Torres, Maria G. Masucci   +3 more
wiley   +1 more source

Making sense of TILs: recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma

Histopathology, EarlyView.
This review examines the role of tumour‐infiltrating lymphocytes (TILs) in gastro‐oesophageal carcinoma (GEC), focusing on their composition, clinical relevance and therapeutic utility. It proposes a framework for standardised evaluation and reporting of TILs, addressing GEC‐specific pathology challenges to support the widespread use and validation of ...
Ylva A Weeda, Roberto Salgado, Filip van Herpe, Daniel Sur, Michael Vieth, Sherene Loi, Ahmad P Tafti, Hardas Alexandros, Akira I Hida, Amarpreet Bhalla, Andrey I Khramtsov, Anna Ehinger, Atsushi Tanaka, Balazs Acs, Caner Ercan, Cornelia M Focke, Daniel Ehinger, Dan Huang, Galina F Khramtsova, Haruto Nishida, Nianyi Li, Nickolas Littlefield, Sanna Steen, Selim Sevim, Shin Ichihara, Shinnosuke Morikawa, Stefan Michiels, Thomas Papathomas, Toshihiro Haga, Qiangqiang Gu, Weiqi Sheng, Hoel Kervadec, Hugo M Horlings, Francisco Sanchez‐Vega, Yelena Y Janjigian, Myriam Chalabi, Hanneke W M van Laarhoven, Liudmila L Kodach, Sybren L Meijer   +38 more
wiley   +1 more source

Analysis of Plasma Epstein–Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE‐122 [PDF]

Cancer Med
ABSTRACT Background Plasma Epstein–Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 ...
Chan A, Lee V, Hong R, Ahn M, Chong W, Spreafico A, Kim S, Ho G, Caguioa P, Ngamphaiboon N, Swaby R, Wei B, Webber A, Kang J, Gumuscu B, Yuan J, Siu L.   +16 more
europepmc   +2 more sources